Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 100 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Follow-Up Questions
MoonLake Immunotherapeutics 的 CEO 是誰？
Dr. Jorge Santos Da Silva 是 MoonLake Immunotherapeutics 的 Chief Executive Officer，自 2022 加入公司。
MLTX 股票的價格表現如何？
MLTX 的當前價格為 $54.16，在上個交易日 decreased 了 0%。
MoonLake Immunotherapeutics 的主要業務主題或行業是什麼？
MoonLake Immunotherapeutics 屬於 Biotechnology 行業，該板塊是 Health Care
